Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
Acquisition of sharesDisclosing companyMEDIKIT CO.,LTD.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
Date of board resolution3 July 2026
Contract Date3 July 2026
Execution Date / Effective Date3 July 2026 (share transfer execution date)
Target company
Research, development and manufacture of medical devices for endovascular treatment
Location Chuo-ku, TokyoShare capital ¥100 millionDate of incorporation 17 June 2020
Net SalesUndisclosed (a startup with no recorded sales)
Operating profitUndisclosed (a startup with no recorded sales)
Net income for the current fiscal yearUndisclosed (a startup with no recorded sales)
Net assetsUndisclosed (a startup with no recorded sales)
Impact on Business Performance
The impact on consolidated results for the fiscal year ending March 2027 is expected to be minor.
Procedures and assumptions
Valuation methodologyDiscussion and negotiation between the parties based on the results of due diligence and an assessment by an independent third-party institution, among other factors
| Item | Details |
|---|---|
| Transaction name | Acquisition of shares |
| Name of the Subject Company | T.G. Medical Co., Ltd. |
| Business Description of the Subject Company | Research, development and manufacture of medical devices for endovascular treatment |
| Location of the Subject Company | Chuo-ku, Tokyo |
| Capital Stock of the Subject Company | ¥100 million |
| Date of Establishment of the Subject Company | 17 June 2020 |
| Net Sales of the Subject Company | Undisclosed (a startup with no recorded sales) |
| Operating Profit of the Subject Company | Undisclosed (a startup with no recorded sales) |
| Net Income of the Subject Company | Undisclosed (a startup with no recorded sales) |
| Net Assets of the Subject Company | Undisclosed (a startup with no recorded sales) |
| Number of shares acquired | 2,211 shares and 331 stock acquisition rights. The number of voting rights is not stated. |
| Voting rights ownership percentage | After 100.0％ (before not disclosed) |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is expected to be minor. |
| Date of board resolution | 3 July 2026 |
| Contract Date | 3 July 2026 |
| Execution Date / Effective Date | 3 July 2026 (share transfer execution date) |
| Valuation methodology | Discussion and negotiation between the parties based on the results of due diligence and an assessment by an independent third-party institution, among other factors |
Items this document does not state (15)
Counterparty nameAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Independent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As part of expanding our business in line with our medium-term management plan, we aim to strengthen the development of products for endovascular treatment of cerebrovascular conditions, while expanding our business operations in Japan and overseas, based on expected synergies with Bolt Medical.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.